Eiji Yamato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eiji Yamato has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Hikaru Matsuda
1 shared publicationHirofumi Makino
1 shared publicationHironori Nakagami
1 shared publicationHitonobu Tomoike
From the Research Institute (K.Komamura, R.T., Y.S., K.Kangawa); Division of Cardiology (K.Komamura, H.T., M.K., K.Miyatake), National Cardiovascular Center; Kyoto Institute of Technology (J.M., K.Matsumoto, E.Y., T.Nakamura), Osaka University, Graduate School of Medicine; Department of Cardiovascular Surgery (T.Nakatani, S.K.), National Cardiovascular Center, Suita, Japan
1 shared publication- Jun-Ichi Miyazaki
Division of Stem Cell Regulation Research, Osaka University Graduate School of Medicine, Suita, Japan
1 shared publication Junya Azuma
1 shared publication
Latest Publications
- 1 September 2004
- Published by Wolters Kluwer Health in Hypertension
- Vol. 44 (3) , 365-371
Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle
Hepatocyte growth factor (HGF) is a potent angiogenic and antifibrotic factor. Cardioprotective effects of HGF for idiopathic dilated cardiomyopathy were examined in hamsters with electroporation of plasmid DNA into skeletal muscle. We used hamster skeletal muscle as a protein producer of HGF gene. A plasmid vector encoding HGF (HGF group, n=12) or empty plasmid (placebo group, n=12) was transferred with in vivo electroporation into tibialis anterior muscles of hamsters with inherited dilated cardiomyopathy (TO-2 strain). The HGF group had greater serum HGF levels (21.6±2.2 versus 0.11±0.07 ng/mL, P P P P P 2 , P P <0.05) than did the placebo group. Exogenous HGF might improve the deleterious changes in myocardial function and structure in the hamster with dilated cardiomyopathy. Systemic delivery of gene products with in vivo electroporation into skeletal muscle seemed to be an alternative means of direct gene delivery.
- 1 September 2004
- Published by Wolters Kluwer Health in Hypertension
- Vol. 44 (3) , 365-371
Treatment of Dilated Cardiomyopathy With Electroporation of Hepatocyte Growth Factor Gene Into Skeletal Muscle
Hepatocyte growth factor (HGF) is a potent angiogenic and antifibrotic factor. Cardioprotective effects of HGF for idiopathic dilated cardiomyopathy were examined in hamsters with electroporation of plasmid DNA into skeletal muscle. We used hamster skeletal muscle as a protein producer of HGF gene. A plasmid vector encoding HGF (HGF group, n=12) or empty plasmid (placebo group, n=12) was transferred with in vivo electroporation into tibialis anterior muscles of hamsters with inherited dilated cardiomyopathy (TO-2 strain). The HGF group had greater serum HGF levels (21.6±2.2 versus 0.11±0.07 ng/mL, P P P P P 2 , P P <0.05) than did the placebo group. Exogenous HGF might improve the deleterious changes in myocardial function and structure in the hamster with dilated cardiomyopathy. Systemic delivery of gene products with in vivo electroporation into skeletal muscle seemed to be an alternative means of direct gene delivery.